<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Non-classic apparent mineralocorticoid excess syndrome: current evidence and future challenges

dc.contributor.authorCarvajal, Cristian A.
dc.contributor.authorTapia-Castillo, Alejandra
dc.contributor.authorUslar, Thomas
dc.contributor.authorVaidya, Anand
dc.contributor.authorPérez, Jorge A.
dc.contributor.authorBaudrand, René
dc.contributor.authorFardella, Carlos E.
dc.coverage.spatialEstados Unidos
dc.date.accessioned2026-11-20T15:26:01Z
dc.date.issued2026-10-30
dc.description.abstractHypertension affects over 1.3 billion people worldwide and is the leading modifiable cause of cardiovascular morbidity and mortality. Approximately one-third of individuals with hypertension exhibit a low-renin phenotype, a clinically heterogeneous subgroup in which the underlying etiology remains uncharacterized in most cases. Among its mechanistic contributors, non-classic apparent mineralocorticoid excess (NC-AME) represents a prevalent and under recognized cause of cortisol-mediated mineralocorticoid receptor over activation that has, to date, lacked a formal clinical definition, standardized diagnostic criteria, or evidence-based therapeutic framework. This review addresses that gap. NC-AME is formally defined as a syndrome of partial 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) insufficiency occurring in the absence of biallelic human HSD11B2 variants, biochemically characterized by an elevated cortisol-to-cortisone (F/E) ratio and low cortisone concentration, and typically associated with low plasma renin, normal-to-low aldosterone, and elevated blood pressure. The review consolidates evidence across 3 mechanistic domains, genetic and epigenetic dysregulation of HSD11B2 gene, endogenous and exogenous enzyme inhibition, and patient-specific alterations (ie, age, sex, renal function), and proposes a structured LC-MS/MS-based diagnostic algorithm, and a resource-adapted diagnostic approach. Mineralocorticoid receptor antagonists are endorsed as mechanism-directed first-line therapy, with blood pressure and renin normalization as co-primary treatment targets. Acquired and reversible causes are classified separately to guide clinical management. A research agenda is advanced to drive threshold standardization, multicenter validation, and integration of NC-AME into hypertension guidelines across endocrinology, cardiology, and nephrology.
dc.identifier.citationEndocrine Reviews, Vol. 00, N° 0 (2026) p. 1-16
dc.identifier.doihttps://doi.org/10.1210/endrev/bnag040
dc.identifier.issn1945-7189
dc.identifier.orcidhttps://orcid.org/0000-0002-0668-412X
dc.identifier.orcidhttps://orcid.org/0000-0002-6081-1468
dc.identifier.orcidhttps://orcid.org/0000-0001-7213-855X
dc.identifier.urihttps://hdl.handle.net/20.500.12254/7861
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofEndocrine reviews
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subjectLow renin hypertension
dc.subjectApparent mineralocorticoid excess
dc.subject11β-hydroxysteroid dehydrogenase type 2
dc.subjectMineralocorticoid receptor
dc.subjectNon-classic AME
dc.subjectCortisol metabolism
dc.titleNon-classic apparent mineralocorticoid excess syndrome: current evidence and future challenges
dc.typeArtículo
oaire.citation.endPage16
oaire.citation.issue00
oaire.citation.startPage1
oaire.citation.volume00

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
2026_Non-classic apparent mineralocorticoid excess syndrome- current evidence and future challenges.pdf
Tamaño:
841,36 KB
Formato:
Adobe Portable Document Format